Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAISTR: Triumeq in HIV with IDU History
NCT02659761Phase 4Terminated
- Sponsor
- University College Dublin
- Start
- Nov 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abacavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University College Dublin. Primary endpoints: Tolerability as assessed by treatment-related adverse events at 96 weeks, Proportion of subjects with unscheduled discontinuation of study treatment at 96 weeks and 2 more. Started Nov 2016; status: terminated.
02
Drugs
abacavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02659761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659761.